Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 11Recruiting 7Completed 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Osteosarcoma 1Neoplasms by Site 1Mouth Neoplasms 1Lung Neoplasms 1Lung Diseases 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Neoplasms 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × camrelizumab × Clear all
NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
441 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
32 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡